- Home
- BIRD vs VANI Comparison
BIRD vs VANI Comparison
Compare BIRD & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- VANI
- Stock Information
- Founded
- BIRD 2015
- VANI 1998
- Country
- BIRD United States
- VANI United States
- Employees
- BIRD N/A
- VANI N/A
- Industry
- BIRD Apparel
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BIRD Consumer Discretionary
- VANI Health Care
- Exchange
- BIRD Nasdaq
- VANI Nasdaq
- Market Cap
- BIRD 89.7M
- VANI 73.5M
- IPO Year
- BIRD 2021
- VANI 2014
- Fundamental
- Price
- BIRD $6.36
- VANI $1.32
- Analyst Decision
- BIRD Buy
- VANI Strong Buy
- Analyst Count
- BIRD 2
- VANI 1
- Target Price
- BIRD $11.00
- VANI $4.00
- AVG Volume (30 Days)
- BIRD 76.8K
- VANI 62.0K
- Earning Date
- BIRD 11-05-2025
- VANI 08-13-2025
- Dividend Yield
- BIRD N/A
- VANI N/A
- EPS Growth
- BIRD N/A
- VANI N/A
- EPS
- BIRD N/A
- VANI N/A
- Revenue
- BIRD $170,646,000.00
- VANI N/A
- Revenue This Year
- BIRD N/A
- VANI N/A
- Revenue Next Year
- BIRD $4.20
- VANI N/A
- P/E Ratio
- BIRD N/A
- VANI N/A
- Revenue Growth
- BIRD N/A
- VANI N/A
- 52 Week Low
- BIRD $3.93
- VANI $0.91
- 52 Week High
- BIRD $14.56
- VANI $1.80
- Technical
- Relative Strength Index (RSI)
- BIRD 37.74
- VANI 53.51
- Support Level
- BIRD $6.28
- VANI $1.18
- Resistance Level
- BIRD $6.81
- VANI $1.40
- Average True Range (ATR)
- BIRD 0.41
- VANI 0.07
- MACD
- BIRD 0.09
- VANI 0.02
- Stochastic Oscillator
- BIRD 20.56
- VANI 67.62
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.